Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Combe

Showing results (181-190 of 282) with videos related to

Pageof 29
Sort By:
Clinical and Experimental Rheumatology|January 24, 2020
Safety of surgery in patients with rheumatoid arthritis treated with tocilizumab: data from the French (REGistry -RoAcTEmra) Regate registryJacques Morel, Marie Locci, Frédéric Banal, et al.
Rheumatology (Oxford, England)|November 4, 2020
Impact of disease activity and treatments on ovarian reserve in patients with rheumatoid arthritis in the ESPOIR cohortCamille Valdeyron, Martin Soubrier, Bruno Pereira, et al.
Expert Review of Clinical Immunology|December 11, 2020
Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysisRoberto Caporali, Yannick Allanore, Rieke Alten, et al.
Joint Bone Spine|April 15, 2018
Relevance and feasibility of a systematic screening of multimorbidities in patients with chronic inflammatory rheumatic diseasesClaire I Daïen, Amandine Tubery, Mégane Beurai-Weber, et al.
The Journal of Rheumatology|March 3, 2011
Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trialEdward C Keystone, Jeffrey R Curtis, Roy M Fleischmann, et al.
Arthritis Research & Therapy|October 24, 2009
Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patientsMichel de Bandt, Bruno Fautrel, Jean Francis Maillefert, et al.
Arthritis and Rheumatism|April 1, 2009
Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferencesBruno Fautrel, Francis Guillemin, Olivier Meyer, et al.
Joint Bone Spine|June 27, 2006
Recommendations of the French Society for Rheumatology. TNFalpha antagonist therapy in rheumatoid arthritisBruno Fautrel, Arnaud Constantin, Jacques Morel, et al.
Arthritis Care & Research|October 10, 2014
Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registrySarah Payet, Martin Soubrier, Elodie Perrodeau, et al.
Annals of the Rheumatic Diseases|June 7, 2013
Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE studyBernard Combe, Bhaskar Dasgupta, Ingrid Louw, et al.
Pageof 29

Showing results (181-190 of 282) with videos related to

Sort By:
Pageof 29
Clinical and Experimental Rheumatology|January 24, 2020
Safety of surgery in patients with rheumatoid arthritis treated with tocilizumab: data from the French (REGistry -RoAcTEmra) Regate registryJacques Morel, Marie Locci, Frédéric Banal, et al.
Rheumatology (Oxford, England)|November 4, 2020
Impact of disease activity and treatments on ovarian reserve in patients with rheumatoid arthritis in the ESPOIR cohortCamille Valdeyron, Martin Soubrier, Bruno Pereira, et al.
Expert Review of Clinical Immunology|December 11, 2020
Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysisRoberto Caporali, Yannick Allanore, Rieke Alten, et al.
Joint Bone Spine|April 15, 2018
Relevance and feasibility of a systematic screening of multimorbidities in patients with chronic inflammatory rheumatic diseasesClaire I Daïen, Amandine Tubery, Mégane Beurai-Weber, et al.
The Journal of Rheumatology|March 3, 2011
Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trialEdward C Keystone, Jeffrey R Curtis, Roy M Fleischmann, et al.
Arthritis Research & Therapy|October 24, 2009
Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patientsMichel de Bandt, Bruno Fautrel, Jean Francis Maillefert, et al.
Arthritis and Rheumatism|April 1, 2009
Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferencesBruno Fautrel, Francis Guillemin, Olivier Meyer, et al.
Joint Bone Spine|June 27, 2006
Recommendations of the French Society for Rheumatology. TNFalpha antagonist therapy in rheumatoid arthritisBruno Fautrel, Arnaud Constantin, Jacques Morel, et al.
Arthritis Care & Research|October 10, 2014
Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registrySarah Payet, Martin Soubrier, Elodie Perrodeau, et al.
Annals of the Rheumatic Diseases|June 7, 2013
Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE studyBernard Combe, Bhaskar Dasgupta, Ingrid Louw, et al.
Pageof 29